DS-2330b

DS-2330b is an investigational **oral small-molecule inhibitor of sodium-dependent phosphate transporter 2b** developed by Daiichi Sankyo for the treatment of hyperphosphatemia in patients with chronic kidney disease, particularly those receiving hemodialysis. It is described in clinical-trial materials as a prodrug or formulated form associated with the free form DS2330a, and was studied as powder-in-bottle solution and tablet formulations administered three times daily. Mechanistically, it was intended to reduce intestinal phosphate absorption by inhibiting NaPi-IIb in the gut. In a phase 1b study in chronic hemodialysis patients, DS-2330b was reported to be generally safe and well tolerated alone or with sevelamer, but it did **not** demonstrate clinically meaningful phosphate-lowering efficacy, suggesting limited clinical utility in this indication.

Other names

DS2330aDS-2330aDS 2330a